Pharmacokinetic parameters such as AUC, maximum plasma concentration (Cmax), terminal elimination t1/2, volume of distribution (Va), and clearance were calculated [1]
Semaglutide lowers cardiovascular risk regardless of blood sugar UTSW-led analysis shows cardiovascular benefits from popular weight-loss drug dont depend on reduction in glucose levels DALLAS June 22, 2024 A weekly dose of semaglutide 2.4 mg significantly reduced the risk of major adverse cardiovascular events (MACEs) in people with overweight or obesity and cardiovascular disease but not diabetes, regardless of blood sugar level, according to a clinical trial including researchers from UT Southwestern Medical Center
To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383)
This growing pipeline means that in the coming years, more oral GLP-1 options could become available, giving patients easier, needle-free ways to manage diabetes and weight
The 28-day timeline applies to Wegovy (single-dose) when stored at room temperature before use, not Ozempic
